VP Medicine Development Lead for HaemophiliaSobi, Basel, SwitzerlandBasel, Stockholms Lan, Sweden
LB 01.1 - Efanesoctocog Alfa Prophylaxis for Previously Treated Patients <12 Years of Age With Severe Hemophilia A
Sunday, June 25, 202310:45 – 11:00 ET
PB0195 - Efanesoctocog Alfa Versus Emicizumab in the Prophylactic Treatment of Adolescents and Adults with Severe Hemophilia A Without Inhibitors: A Matching-Adjusted Indirect Comparison
Sunday, June 25, 202318:30 – 19:30 ET
OC 69.5 - Outcomes in Adult and Adolescent Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis From an Observational Study With Factor VIII Prophylaxis
Wednesday, June 28, 202311:15 – 11:30 ET
